A phase 1 evaluation of 64Cu-DOTA-patritumab to assess dosimetry, receptor occupancy, and safety in advanced solid tumors

Authors
Category Primary study
JournalCancer Research
Year 2014
This article has no abstract
Epistemonikos ID: d6941fff8b679b756db173c25478571209c9e366
First added on: Feb 06, 2025